Ingrid A. Mayer, M.D., M.S.C.I.
- Co-Leader, Breast Cancer Research Program
- Professor of Medicine (Hematology/Oncology)
- Ingram Professor of Cancer Research
- Chair, Data and Safety Monitoring Committee
Phone
2220 Pierce Ave.
777 Preston Building
Nashville, TN 37232-6307
Ingrid A. Mayer, M.D., M.S.C.I.
- Co-Leader, Breast Cancer Research Program
- Professor of Medicine (Hematology/Oncology)
- Ingram Professor of Cancer Research
- Chair, Data and Safety Monitoring Committee
615-936-3831
ingrid.mayer@Vanderbilt.Edu
2220 Pierce Ave.
777 Preston Building
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Mayer obtained her medical degree from the Federal University of Sáo Paulo, Brazil in 1993. Thereafter, she came to the United States for her post-graduate training (internship, residency, chief-residency and Hematology/ Oncology fellowship) at the University of Illinois at Chicago, between 1994 and 2001. During that time, Dr. Mayer received an American Society of Clinical Oncology (ASCO) Young Investigator Award in 2001 for her research project focused on the inhibitory effects of IFN-alpha in chronic myelogenous leukemia.
In September, 2003, Dr. Mayer was recruited to Vanderbilt University as an Assistant Professor of Medicine and member of the Breast Cancer Program of the NCI-designated Vanderbilt-Ingram Cancer Center (VICC). She successfully completed a Master of Science in Clinical Investigation (MSCI) Program at Vanderbilt University in May 2006. Since then, she displayed an impressively strong commitment to a career in patient-oriented clinical and translational research in breast cancer. Her research endeavors have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers. She has obtained several grants to fund her line of research, including a K23 Career Development Award, a Breast Cancer Research Foundation - American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research, and co-leadership in 3 projects in 2 of the VICC Breast Cancer Specialized Program of Research Excellence (SPORE) Grants.
Dr. Mayer has been a Principal Investigator on more than 50 clinical trials, spanning from phase I through phase III trials. Of these, more than 10 are investigator-initiated trials (IITs), including two large Cooperative Group phase III trials through the Eastern Cooperative Oncology Group- American College of Radiology Imaging Network (ECOG-ACRIN) and a global Stand Up to Cancer (SU2C) / Translational Breast Cancer Research Consortium (TBCRC) / Novartis trial. In view of her clinical trial experience, she was appointed Chair of the Data Safety and Monitoring Committee (VICC DSMC) in 2010.
Nationally, aside from being an active member of the ECOG-ACRIN Breast Core Committee, and the VICC representative of the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Dr. Mayer has been highly involved with the Translational Breast Cancer Research Consortium (TBCRC), and since 2009, she was appointed co-Chair of the TBCRC Endocrine Resistance Working Group (ERWG).
As a key component of the VICC Breast Cancer Program, Dr. Mayer has been the director of the Clinical Core of the VICC Breast Cancer SPORE and Clinical Team Leader of the Breast Cancer Program since 2008. In this capacity, Dr. Mayer oversees and coordinates the efforts of several physicians and full-time research support personnel, assisting with implementation and development of investigator-initiated, mechanism-based translational clinical trials, patient accrual, management, and monitoring of toxicity of patients on the trials. Under her leadership, the Breast Cancer Research Team is currently one of the top accruer of patients to VICC trials, and in 2014 she was appointed Co-Leader of the VICC Breast Cancer Program.
Education
- M.S.C.I., Vanderbilt University, Nashville, Tennessee (2006)
- M.D., Universidade de Sao Paulo, Sao Paulo, Brazil (1993)
- Residency, Internal Medicine, University of Illinois at Chicago Affiliated Hospitals, Chicago, IL (July 1994 - June 1997)
- Chief Residency, Internal Medicine, University of Illinois at Chicago Affiliated Hospitals, Chicago, IL (July 1997 - June 1998)
- Fellowship, Hematology/OncologyUniversity of Illinois at Chicago Affiliated Hospitals, Chicago, IL (July 1998 - June 2001)
Research Emphasis
Breast Cancer - Targeted Therapies
Research Description
Dr. Mayer obtained her medical degree from the Federal University of São Paulo, Brazil in 1993. Thereafter, she came to the United States for her post-graduate training (internship, residency, chief-residency and Hematology/ Oncology fellowship) at the University of Illinois at Chicago, between 1994 and 2001. In September, 2003, Dr. Mayer was recruited to Vanderbilt University Medical Center (VUMC)/ Vanderbilt-Ingram Cancer Center (VICC), and successfully completed a Master of Science in Clinical Investigation (MSCI) Program at Vanderbilt University School of Medicine in May 2006. Since then, her research endeavors have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers. Dr. Mayer is currently the co-director of the VICC Breast Cancer SPORE and Leader of the VICC Breast Cancer Program. She has been a Principal Investigator on more than 80 breast cancer clinical trials, spanning from phase I through phase III trials. In view of her clinical trial experience, she was appointed Chair of the Data Safety and Monitoring Committee (VICC DSMC) in 2010. Nationally, aside from being an active member of the ECOG-ACRIN Breast Core Committee, and the VICC representative of the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Dr. Mayer has been highly involved with the Translational Breast Cancer Research Consortium (TBCRC), and since 2009, she was appointed co-Chair of the TBCRC Endocrine Resistance Working Group (ERWG).
Publications
- Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB. Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. J. Clin. Oncol [print-electronic]. 2018 Sep 9/20/2018; JCO2017748392. PMID: 30235087, DOI: 10.1200/JCO.2017.74.8392, ISSN: 1527-7755.
- Schöffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, Rooney I, Morrissey KM, Spoerke JM, Ng VW, Singel SM, Winer E. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Res. 2018 Sep 9/5/2018; 20(1): 109. PMID: 30185228, PMCID: PMC6125885, PII: 10.1186/s13058-018-1015-x, DOI: 10.1186/s13058-018-1015-x, ISSN: 1465-542X.
- Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J. Clin. Oncol [print-electronic]. 2018 Sep 9/1/2018; 36(25): 2621-9. PMID: 30040523, PMCID: PMC6118403, DOI: 10.1200/JCO.2018.79.2028, ISSN: 1527-7755.
- Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N. Engl. J. Med [print-electronic]. 2018 Jul 7/12/2018; 379(2): 111-21. PMID: 29860917, DOI: 10.1056/NEJMoa1804710, ISSN: 1533-4406.
- Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol [print-electronic]. 2018 Jun; 19(6): 812-24. PMID: 29706375, PII: S1470-2045(18)30147-5, DOI: 10.1016/S1470-2045(18)30147-5, ISSN: 1474-5488.
- Croessmann S, Sheehan JH, Lee KM, Sliwoski G, He J, Nagy R, Riddle D, Mayer IA, Balko JM, Lanman R, Miller VA, Cantley LC, Meiler J, Arteaga CL. PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Ka Inhibitors. Clin. Cancer Res [print-electronic]. 2018 Mar 3/15/2018; 24(6): 1426-35. PMID: 29284706, PMCID: PMC5856622, PII: 1078-0432.CCR-17-2141, DOI: 10.1158/1078-0432.CCR-17-2141, ISSN: 1078-0432.
- Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature [print-electronic]. 2018 Feb 2/8/2018; 554(7691): 189-94. PMID: 29420467, PMCID: PMC5808581, PII: nature25475, DOI: 10.1038/nature25475, ISSN: 1476-4687.
- Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS. Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. Target Oncol. 2018 Feb; 13(1): 61-8. PMID: 29218624, PMCID: PMC5826865, PII: 10.1007/s11523-017-0542-1, DOI: 10.1007/s11523-017-0542-1, ISSN: 1776-260X.
- Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res. Treat [print-electronic]. 2018 Feb; 167(3): 731-40. PMID: 29110152, PMCID: PMC5821069, PII: 10.1007/s10549-017-4533-9, DOI: 10.1007/s10549-017-4533-9, ISSN: 1573-7217.
- Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Association of FGFR1 with ERa Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clin. Cancer Res [print-electronic]. 2017 Oct 10/15/2017; 23(20): 6138-50. PMID: 28751448, PII: 1078-0432.CCR-17-1232, DOI: 10.1158/1078-0432.CCR-17-1232, ISSN: 1078-0432.
